Patents by Inventor Richard A Partis

Richard A Partis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrazoles as p38 kinase inhibitors
    Patent number: 6617324
    Abstract: A class of pyrazole derivatives described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: September 9, 2003
    Assignee: G. D. Searle & Company
    Inventors: Ashok S. Naraian, Michael Clare, Paul W. Collins, Joyce Zuowu Crich, Rajesh Devraj, Daniel L. Flynn, Lifeng Geng, Matthew J. Graneto, Cathleen E. Hanau, Gunnar J. Hanson, Susan J. Hartmann, Michael Hepperle, He Huang, Francis J. Koszyk, Shuyuan Liao, Suzanne Metz, Richard A. Partis, Thao D. Perry, Shashidhar N. Rao, Shaun Raj Selness, Michael S. South, Michael A. Stealey, John Jeffrey Talley, Michael L. Vazquez, Richard M. Weier, Xiangdong Xi, Ish K. Khanna, Yi Yu
  • Heterocyclo-substituted imidazoles for the treatment of inflammation
    Patent number: 6613789
    Abstract: A class of imidazolyl compounds is described for use in treating inflammation. Compounds of particular interest are defined by Formula V: and pharmaceutically-acceptable salts thereof.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: September 2, 2003
    Assignee: G. D. Searle & Co.
    Inventors: Ish K. Khanna, Richard M. Weier, Paul W. Collins, Yi Yu, Xiangdong Xu, Richard A. Partis, Francis J. Koszyk, Renee M. Huff
  • 3 (5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
    Patent number: 6579873
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I wherein R1, R2, Ar1 and HetAr2 are as described in the specification.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: June 17, 2003
    Assignee: Pharmacia Corporation
    Inventors: Ashok Anantanarayan, Michael Clare, Lifeng Geng, Gunnar J. Hanson, Richard A. Partis, Michael A. Stealey, Richard M. Weier
  • Substituted indazole compounds for the treatment of inflammation
    Publication number: 20030109550
    Abstract: The present invention relates to substituted indazole derivatives, compositions comprising such, intermediates, methods of making substituted indazolel derivatives, and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis.
    Type: Application
    Filed: September 19, 2002
    Publication date: June 12, 2003
    Inventors: Michael Clare, Joyce Z. Crich, Francis J. Koszyk, Richard A. Partis, Michael A. Stealey, Richard M. Weier, Xiangdong Xu, Cathleen E. Hanau
  • Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
    Patent number: 6545021
    Abstract: N-Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds of Formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections, the compounds of Formula I may be used alone, or in combination with another antiviral agent selected from among nucleosides, nucleotides, immunomodulators, immunostimulats or various combinations of such other agents.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: April 8, 2003
    Assignee: G.D. Searle & Co.
    Inventors: Richard A. Mueller, Martin L. Bryant, Richard A. Partis
  • Substituted pyrazoles as p38 kinase inhibitors
    Patent number: 6525059
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R 2, R3 and R4 are as described in the specification.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: February 25, 2003
    Assignee: G. D. Searle & Company
    Inventors: Ashok Anantanarayan, Michael Clare, Paul W. Collins, Joyce Zuowu Crich, Rajesh Devraj, Daniel L. Flynn, Lifeng Geng, Matthew J. Graneto, Cathleen E. Hanau, Gunnar J. Hanson, Susan J. Hartmann, Michael Hepperle, He Huang, Francis J. Koszyk, Shuyuan Liao, Suzanne Metz, Richard A. Partis, Thao D. Perry, Shashidhar N. Rao, Shaun Raj Selness, Michael S. South, Michael A. Stealey, John Jeffrey Talley, Michael L. Vazquez, Richard M. Weier, Xiangdong Xu, Ish K. Khanna, Yi Yu
  • Heterocyclo-substituted imidazoles for the treatment of inflammation
    Publication number: 20030036557
    Abstract: A class of imidazolyl compounds is described for use in treating inflammation.
    Type: Application
    Filed: December 5, 2001
    Publication date: February 20, 2003
    Applicant: G.D. Searle & Co.
    Inventors: Ish K. Khanna, Richard M. Weier, Paul W. Collins, Yi Yu, Xiangdong Xu, Richard A. Partis, Francis J. Koszyk, Renee M. Huff
  • Glucamine compounds for treating hepatitis virus infections
    Patent number: 6515028
    Abstract: N-Substituted glucamine compounds of Formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections, the compounds of Formula I may be used alone, or in combination with another antiviral agents selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: February 4, 2003
    Assignee: G.D. Searle & Co.
    Inventors: Richard A. Mueller, Martin L. Bryant, Richard A. Partis
  • Substituted pyrazoles as p38 kinase inhibitors
    Patent number: 6514977
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.
    Type: Grant
    Filed: November 20, 1998
    Date of Patent: February 4, 2003
    Assignee: G.D. Searle & Company
    Inventors: Ashok Anantanarayan, Michael Clare, Paul W. Collins, Joyce Zuowu Crich, Rajesh Devraj, Daniel L. Flynn, Lifeng Geng, Matthew J. Graneto, Cathleen E. Hanau, Gunnar J. Hanson, Susan J. Hartmann, Michael Hepperle, He Huang, Francis J. Koszyk, Shuyuan Liao, Suzanne Metz, Richard A. Partis, Thao D. Perry, Shashidhar N. Rao, Shaun Raj Selness, Michael S. South, Michael A. Stealey, John Jeffrey Talley, Michael L. Vazquez, Richard M. Weier, Xiangdong Xu, Ish K. Khanna, Yi Yu
  • Substituted pyrazoles as p38 kinase inhibitors
    Patent number: 6423713
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: July 23, 2002
    Assignee: G. D. Searle & Company
    Inventors: Ashok Anantanarayan, Michael Clare, Paul W. Collins, Joyce Zuowu Crich, Rajesh Devraj, Daniel L. Flynn, Lifeng Geng, Matthew J. Graneto, Cathleen E. Hanau, Gunnar J. Hanson, Susan J. Hartmann, Michael Hepperle, He Huang, Francis J. Koszyk, Shuyuan Liao, Suzanne Metz, Richard A. Partis, Thao D. Perry, Shashidhar N. Rao, Shaun Raj Selness, Michael S. South, Michael A. Stealey, John Jeffrey Talley, Michael L. Vazquez, Richard M. Weier, Xiangdong Xi, Ish K. Khanna, Yi Yu
  • 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors
    Publication number: 20020086869
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders.
    Type: Application
    Filed: December 18, 2001
    Publication date: July 4, 2002
    Inventors: Ashok Anantanarayan, Michael Clare, Lifeng Geng, Gunnar J. Hanson, Richard A. Partis, Michael A. Stealey, Richard M. Weier
  • 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
    Patent number: 6335336
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: January 1, 2002
    Assignee: G.D. Searle & Company
    Inventors: Ashok Anantanarayan, Michael Clare, Lifeng Geng, Gunnar J. Hanson, Richard A. Partis, Michael A. Stealey, Richard M. Weier
  • Halogenated phenylacetonitrile alkylaminoalkylphenyl compounds as immunosuppressives
    Patent number: 6265439
    Abstract: A class of halogenated phenylacetonitrile alkylaminoalkylphenyl compounds having immunosuppressive properties is described. Compounds of this class would be useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune or inflammatory diseases.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: July 24, 2001
    Assignee: G.D. Searle & Co.
    Inventors: Richard A Mueller, Thomas E Barta, John P McKearn, Susan A Gregory, Richard A Partis, Francis J Koszyk
  • Substituted pyrazoles suitable as p38 kinase inhibitors
    Patent number: 6087496
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I: ##STR1## wherein R.sup.1, R.sup.2, Ar.sup.1 and HetAr.sup.2 are as described in the specification.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: July 11, 2000
    Assignee: G. D. Searle & Co.
    Inventors: Ashok Anantanarayan, Michael Clare, Lifeng Geng, Gunnar J. Hanson, Richard A. Partis, Michael A. Stealey, Richard M. Weier
  • 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
    Patent number: 5932576
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: August 3, 1999
    Assignee: G. D. Searle & Company
    Inventors: Ashok Anantanarayan, Michael Clare, Lifeng Geng, Gunnar J. Hanson, Richard A. Partis, Michael A. Stealey, Richard M. Weier
  • 2,3-substituted pyridines for the treatment of inflammation
    Patent number: 5916905
    Abstract: A class of substituted pyridyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II wherein R.sup.1 is selected from hydrido, halo, alkoxy, haloalkoxy, aryl, alkylthio, alkylamino, aralkoxy, azido and alkenyloxy; wherein R.sup.2 is selected from hydrido, cyano, hydroxyalkyl, haloalkyl, aminoalkyl, alkylaminoalkyl, alkylcarbonyloxyalkyl, aminocarbonyl and alkylcarbonylaminoalkyl; and wherein R.sup.5 and R.sup.6 are one or more radicals independently selected from halo, alkylsulfonyl, aminosulfonyl, alkoxy and alkylthio; provided one of R.sup.5 and R.sup.6 is substituted with alkylsulfonyl, aminosulfonyl, or haloalkylsulfonyl; or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: June 29, 1999
    Assignee: G. D. Searle & Co.
    Inventors: Richard M Weier, Len F Lee, Richard A Partis, Francis J Koszyk
  • 2, 3-substituted pyridines for the treatment of inflammation
    Patent number: 5686470
    Abstract: A class of substituted pyridyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II ##STR1## wherein R.sup.1 is selected from hydrido, halo, alkoxy, haloalkoxy, aryl, alkylthio, alkylamino, aralkoxy, azido and allyloxy; wherein R.sup.2 is selected from hydrido, cyano, hydroxyalkyl, haloalkyl, aminoalkyl, aminocarbonyl and alkylcarbonylaminoalkyl; and wherein R.sup.5 and R.sup.6 are one or more radicals independently selected from halo, alkylsulfonyl, aminosulfonyl, alkoxy and alkylthio; provided one of R.sup.5 and R.sup.6 is substituted with alkylsulfonyl, aminosulfonyl, or haloalkylsulfonyl; or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: February 10, 1995
    Date of Patent: November 11, 1997
    Inventors: Richard M. Weier, Len F. Lee, Richard A. Partis, Francis J. Koszyk
  • Method for treating a mammal infected with respiratory syncytial virus
    Patent number: 5622972
    Abstract: A method is provided for treating a mammal infected with respiratory syncytial virus (RSV) comprising administering to the mammal an RSV inhibitory effective amount of a compound or its pharmaceutically acceptable salt of the formula ##STR1## wherein R.sup.1 is alkyl, aralkyl, aroyl or acyl and R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H or acyl.
    Type: Grant
    Filed: January 26, 1996
    Date of Patent: April 22, 1997
    Assignee: G. D. Searle & Co.
    Inventors: Martin L. Bryant, Francis J. Koszyk, Richard A. Mueller, Richard A. Partis
  • 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
    Patent number: 5616601
    Abstract: A class of imidazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: ##STR1## wherein R.sup.1 -R.sup.6 are as described in the specification; or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 1, 1997
    Assignee: GD Searle & Co
    Inventors: Ish K. Khanna, Richard M. Weier, Paul W. Collins, Yi Yu, Xiangdong Xu, Richard A. Partis, Francis J. Koszyk
  • Derivatives of cyclic phenolic thioethers
    Patent number: 5476944
    Abstract: The present invention relates to derivatives of cyclic phenolic thioethers of the formula: ##STR1## and the pharmaceutically acceptable salts thereof, which are inhibitors or stimulators of superoxide generation, and which may also inhibit cyclooxygenase and/or 5-lipoxygenase, to pharmaceutical compositions containing one or more of these compounds in combination with a pharmaceutically-acceptable carrier, and to medical methods of treatment employing these compounds.
    Type: Grant
    Filed: May 19, 1994
    Date of Patent: December 19, 1995
    Assignee: G. D. Searle & Co.
    Inventors: Richard A. Partis, Richard A. Mueller, Francis J. Koszyk, Richard M. Weier